NCT00938652_2C | R Documentation |
Kaplan-Meier digitized data from NCT00938652, figure 2C (PMID 25349301). A reported sample size of 519 for a primary endpoint of OS/PFS in breast cancer.
NCT00938652_2C
A data frame of 519 observations and 3 variables:
time | event time (in months) | |
event | PFS event indicator (0 : no event, 1 : event) |
|
arm | treatment arms (gc, gci) | |
O’Shaughnessy J, Schwartzberg L, Danso MA, et al. Phase III study of iniparib plus gemcitabine and carboplatin versus gemcitabine and carboplatin in patients with metastatic triple-negative breast cancer. J Clin Oncol 2014; 32: 3840–7.
summary(NCT00938652_2C)
kmplot(NCT00938652_2C)
Add the following code to your website.
For more information on customizing the embed code, read Embedding Snippets.